Phase 3 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have previously been diagnosed with multiple myeloma and have already received between 1 and 4 rounds of treatment, including a type of drug that targets a protein called CD38 and a drug called lenalidomide.
• People whose myeloma has started growing again or did not respond to their most recent treatment.
• People whose myeloma can be measured through specific blood or urine tests showing certain protein levels above defined thresholds (confirm with trial site for exact values).
• People whose recent blood test results fall within the ranges required by the trial (confirm with trial site for exact values).
• People who are reasonably well and able to carry out daily activities, based on a standard medical fitness scale — broadly, those who are fully active or have only mild limitations.
• People who are not pregnant or breastfeeding, and who are willing to use contraception during the trial.

Who may not be able to join:

• People who have a slow-growing, early form of myeloma that has not yet required treatment (smoldering multiple myeloma).
• People who have a condition where myeloma cells are present in the blood (plasma cell leukemia).
• People who have a condition called amyloidosis, where abnormal proteins build up in organs.
• People who have a rare condition called POEMS syndrome, which affects multiple body systems including the nerves and organs.
• People who have myeloma that has spread to the brain or spinal fluid, or who show signs of this.
• People who have had a stem cell transplant within the 12 weeks before joining, or who are experiencing complications from a previous transplant where the donor cells are attacking the body.
• People who currently have an active, uncontrolled infection caused by bacteria, fungi, or a virus.
• People who have had another cancer within the past 3 years (with some exceptions, such as certain treated skin cancers or very early-stage cancers that have not spread).
• People who have previously received a treatment that targets a protein called BCMA, or a treatment that redirects a type of immune cell called a T cell (CD3-redirecting therapy).
• People who are unable to receive the treatment options offered by the trial doctors.
• People who have received a live vaccine within 4 weeks before starting the trial.
• People who have taken part in another clinical trial or received an experimental treatment within 30 days before starting this trial.

Important: Always verify eligibility with the trial site directly before applying.